title: Lipid-Polymer Nanoparticles for Folate-Receptor Targeting Delivery of Doxorubicin.
abstract: A biocompatible PLGA-lipid hybrid nanoparticles (NPs) was developed for targeted delivery of anticancer drugs with doxorubicin (DOX). The hydrodynamic diameter and zeta potential of DOX-loaded PLGA-lipid NPs (DNPs) were affected by the mass ratio of Lipid/PLGA or DSPE-PEG-COOH/Lecithin. At the 1:20 drug/polymer mass ratio, the mean hydrodynamic diameter of DNPs was the lowest (99.2 1.83 nm) and the NPs presented the encapsulation efficiency of DOX with 42.69 1.30%. Due to the folate-receptor mediated endocytosis, the PLGA-lipid NPs with folic acid (FA) targeting ligand showed significant higher uptake by folate-receptor-positive MCF-7 cells as compared to PLGA-lipid NPs without folate. Confocal microscopic observation and flow cytometry analysis also supported the enhanced cellular uptake of the FA-targeted NPs. The results indicated that the FA-targeted DNPs exhibited higher cytotoxicity in MCF-7 cells compared with non-targeted NPs. The lipid-polymer nanoparticles provide a solution of biocompatible nanocarrier for cancer targeting therapy.
authors.forename: Mingbin
authors.initials: M
authors.lastname: Zheng
authors.forename: Ping
authors.initials: P
authors.lastname: Gong
authors.forename: Cuifang
authors.initials: C
authors.lastname: Zheng
authors.forename: Pengfei
authors.initials: P
authors.lastname: Zhao
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: Luo
authors.forename: Yifan
authors.initials: Y
authors.lastname: Ma
authors.forename: Lintao
authors.initials: L
authors.lastname: Cai
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D058973:Folate Receptors, GPI-Anchored / Q000819:agonists*; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D054709:Lecithins / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
chemical_list: D000903:Antibiotics, Antineoplastic; D058973:Folate Receptors, GPI-Anchored; D054709:Lecithins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D004317:Doxorubicin